These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 9157298

  • 21. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital.
    Pittayanon R, Treeprasertsuk S, Phanthumchinda K.
    J Med Assoc Thai; 2009 Apr; 92(4):478-82. PubMed ID: 19374297
    [Abstract] [Full Text] [Related]

  • 22. Plasmapheresis in the treatment of myasthenia gravis.
    Lenzhofer R, Graninger W, Dittrich C, Mamoli B, Zeitlhofer J, Pateisky K.
    Wien Klin Wochenschr; 1983 Apr 15; 95(8):266-71. PubMed ID: 6603717
    [Abstract] [Full Text] [Related]

  • 23. Plasmapheresis: a new treatment modality for the patient with severe myasthenia gravis.
    Eppel M, Streib EW.
    Nebr Med J; 1982 Apr 15; 67(4):72-4. PubMed ID: 7088214
    [No Abstract] [Full Text] [Related]

  • 24. [Electroacupuncture warming therapy combined with western medicine for treatment of myasthenia gravis and effect on IL-4 level in the patients].
    Wang SH, Cui X, Feng J.
    Zhongguo Zhen Jiu; 2007 Dec 15; 27(12):901-3. PubMed ID: 18271233
    [Abstract] [Full Text] [Related]

  • 25. [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia].
    Pérez Nellar J, Domínguez AM, Llorens-Figueroa JA, Ferrá-Betancourt A, Pardo A, Quiala M, Gali Z.
    Rev Neurol; 2007 Dec 15; 33(5):413-6. PubMed ID: 11727205
    [Abstract] [Full Text] [Related]

  • 26. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up.
    Triantafyllou NI, Grapsa EI, Kararizou E, Psimenou E, Lagguranis A, Dimopoulos A.
    Ther Apher Dial; 2009 Jun 15; 13(3):174-8. PubMed ID: 19527462
    [Abstract] [Full Text] [Related]

  • 27. Thymectomy in the treatment of ocular myasthenia gravis.
    Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR.
    J Thorac Cardiovasc Surg; 2001 Sep 15; 122(3):562-8. PubMed ID: 11547310
    [Abstract] [Full Text] [Related]

  • 28. Plasma exchange therapy for severe penicillamine-induced myasthenia gravis.
    Lang AE, Humphrey JG, Gordn DA.
    J Rheumatol; 1981 Sep 15; 8(2):303-7. PubMed ID: 7230162
    [Abstract] [Full Text] [Related]

  • 29. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable.
    Mandawat A, Mandawat A, Kaminski HJ, Shaker ZA, Alawi AA, Alshekhlee A.
    Muscle Nerve; 2011 Apr 15; 43(4):578-84. PubMed ID: 21404289
    [Abstract] [Full Text] [Related]

  • 30. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis.
    Köhler W, Bucka C, Klingel R.
    J Clin Apher; 2011 Dec 15; 26(6):347-55. PubMed ID: 22095647
    [Abstract] [Full Text] [Related]

  • 31. Long-term clinical outcome after extended thymectomy combined postoperative high-dose steroid therapy for juvenile myasthenia gravis.
    Kanzaki M, Obara T, Sasano S, Hikawa Y, Onuki T.
    Ann Thorac Cardiovasc Surg; 2008 Apr 15; 14(2):119-22. PubMed ID: 18414352
    [Abstract] [Full Text] [Related]

  • 32. Plasma exchange in elderly patients.
    Basic-Jukic N, Brunetta B, Kes P.
    Ther Apher Dial; 2010 Apr 15; 14(2):161-5. PubMed ID: 20438537
    [Abstract] [Full Text] [Related]

  • 33. Clinical predictors of steroid-induced exacerbation in myasthenia gravis.
    Bae JS, Go SM, Kim BJ.
    J Clin Neurosci; 2006 Dec 15; 13(10):1006-10. PubMed ID: 17074487
    [Abstract] [Full Text] [Related]

  • 34. [Intensive therapy of myasthenia gravis].
    Henze T.
    Psychiatr Neurol Med Psychol Beih; 1988 Dec 15; 40():74-8. PubMed ID: 3146087
    [No Abstract] [Full Text] [Related]

  • 35. [Plasmapheresis in patients with myasthenia gravis].
    Konishi T.
    Nihon Rinsho; 2008 Jun 15; 66(6):1165-71. PubMed ID: 18540364
    [Abstract] [Full Text] [Related]

  • 36. [Predictive factors of the response to treatment of myasthenia gravis with prednisone].
    Pradas J, Illa I.
    Neurologia; 1990 Jan 15; 5(1):11-3. PubMed ID: 2361025
    [Abstract] [Full Text] [Related]

  • 37. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.
    Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C.
    Ann Neurol; 1997 Jun 15; 41(6):789-96. PubMed ID: 9189040
    [Abstract] [Full Text] [Related]

  • 38. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure.
    Stegmayr BG, Banga R, Berggren L, Norda R, Rydvall A, Vikerfors T.
    Crit Care Med; 2003 Jun 15; 31(6):1730-6. PubMed ID: 12794412
    [Abstract] [Full Text] [Related]

  • 39. Plasmapheresis therapy in myasthenia gravis.
    Dau PC.
    Muscle Nerve; 1980 Jun 15; 3(6):468-82. PubMed ID: 7453714
    [Abstract] [Full Text] [Related]

  • 40. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J.
    Semin Neurol; 2003 Jun 15; 23(2):191-8. PubMed ID: 12894384
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.